Key result
Elevated serum and urinary miR-652-3p predicts AKI onset and poor 180-day survival in ADHF.
Why the study?
This study aimed to examine miR-652-3p to improve early diagnosis of AKI in patients with ADHF and evaluate its survival predictive value.
Does miR-652-3p level predict acute kidney injury onset and 180-day survival in patients with acute decompensated heart failure?
Cohort (n=196)
Does miR-652-3p level predict acute kidney injury onset and 180-day survival in patients with acute decompensated heart failure?
Serum and urinary miR-652-3p, especially combined with NGAL, may serve as a useful biomarker for early diagnosis and prognosis of AKI in patients with acute decompensated heart failure.
OBJECTIVE: This study aimed to examine a novel microRNA (miR-652-3p) biomarker to improve early diagnosis of acute kidney injury (AKI) in patients with acute decompensated heart failure (ADHF) and to evaluate the survival predictive value of miR-652-3p. METHODS: We retrospectively analyzed the data of 196 patients with ADHF, including 65 who developed AKI during hospitalization. Neutrophil gelatinase-associated lipocalin (NGAL) levels were measured in serum and urine samples. Real-time quantitative PCR was applied to evaluate miR-652-3p mRNA expression. The diagnostic performance of miR-652-3p was examined using receiver operating characteristic curve analysis. The prognostic value of miR-652-3p was also analyzed. RESULTS: Serum and urinary NGAL and miR-652-3p levels were elevated in patients with ADHF and AKI. Serum and urinary miR-652-3p expression had diagnostic value in predicting AKI onset in patients with ADHF, and it had improved diagnostic performance when used with NGAL. Patients with AKI and high miR-652-3p levels had a high failure rate of renal recovery and poor 180-day survival. CONCLUSION: Serum and urinary miR-652-3p may be a candidate biomarker for early diagnosis of AKI in patients with ADHF and for predicting the prognosis of AKI. The combination of NGAL and miR-652-3p may accurately predict AKI onset in ADHF.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2020) conducted a cohort in Acute decompensated heart failure and acute kidney injury (n=196). Elevated miR-652-3p levels was evaluated on Acute kidney injury onset. Elevated serum and urinary miR-652-3p levels predicted acute kidney injury onset in patients with acute decompensated heart failure and were associated with poor 180-day survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: